Bin He, Jianing Sun, Yajuan An, Qiaorui Tan, Honglin Xu, Jintao Jiang, Xin Chen, Youfen Yao, Jing Li
{"title":"Baicalein attenuates bleomycin-induced pulmonary fibrosis via endothelial Piezo1-associated Ca<sup>2+</sup>/calpain-MAPK signaling and EndMT-associated remodeling.","authors":"Bin He, Jianing Sun, Yajuan An, Qiaorui Tan, Honglin Xu, Jintao Jiang, Xin Chen, Youfen Yao, Jing Li","doi":"10.1016/j.bioorg.2026.110664","DOIUrl":"https://doi.org/10.1016/j.bioorg.2026.110664","url":null,"abstract":"<p><p>Pulmonary fibrosis is a progressive fibrotic lung disorder in which chemical injury, inflammation, extracellular matrix deposition, and endothelial dysfunction converge to remodel lung architecture. Baicalein, a chemically defined flavonoid, has reported anti-inflammatory and antifibrotic activity, but the endothelial mechanotransduction events linked to its effects in bleomycin-induced fibrosis remain insufficiently defined. Here, we evaluated whether baicalein modulates endothelial Piezo1-associated signaling during experimental pulmonary fibrosis. A bleomycin-induced mouse model, endothelial cell-specific Piezo1 knockout mice, primary mouse pulmonary microvascular endothelial cells (PMECs), and HUVEC-based mechanistic assays were used to examine lung injury, collagen accumulation, endothelial-to-mesenchymal transition (EndMT), calcium influx, calpain activity, and MAPK activation. Baicalein reduced bleomycin-associated lung inflammation, collagen deposition, hydroxyproline accumulation, and EndMT-associated marker changes. Mechanistically, baicalein lowered Piezo1 expression and Piezo1-associated Ca<sup>2+</sup> influx in endothelial cells, accompanied by reduced calpain activity and decreased phosphorylation of p38, ERK, and JNK. Endothelial Piezo1 deletion attenuated bleomycin-induced fibrotic remodeling and partially blunted the additional protective response to baicalein, supporting the functional involvement of endothelial Piezo1 while not excluding Piezo1-independent effects. These findings suggest that baicalein alleviates experimental pulmonary fibrosis, at least in part, by modulating the endothelial Piezo1/Ca<sup>2+</sup>/calpain-MAPK signaling axis and suppressing EndMT-associated changes. The data support endothelial mechanotransduction as a pharmacologically relevant node in fibrotic lung injury, but direct baicalein-Piezo1 binding, pathway epistasis, pharmacokinetics, and long-term safety require further validation.</p>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"184 ","pages":"110664"},"PeriodicalIF":5.1,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149223036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A tumor-targeting strategy based on covalent aptamer-carborane conjugates.","authors":"Xiaolu Zhou, Shaokang Jia, Shengjie Xie, Shanshan Qin, Xiang Zhou","doi":"10.1016/j.bioorg.2026.110553","DOIUrl":"10.1016/j.bioorg.2026.110553","url":null,"abstract":"<p><p>The development of tumor-targeting agents is of great significance for cancer therapy. Despite the promising potential of Boron Neutron Capture Therapy (BNCT), efficient and selective accumulation of boron-10 agents in cancer cells remains challenging. Conjugation of carborane with tumor-targeting ligands provides an alternative strategy for selective accumulation in the vicinity of cancer cells. In this study, we designed and synthesized aptamer-carborane derivatives, named AS1411-CB conjugates, via covalent linkage between a dodecahydro-arachno-bis(acetonitrile)decaborane and the DNA aptamer AS1411. AS1411 specifically binds to nucleolin, which is frequently overexpressed on the surface of cancer cells, thus enables selective targeting. Circular dichroism analysis indicated that AS1411-CB conjugates retained the characteristic G-quadruplex conformation of AS1411. Incorporation of a 5-Carboxyfluorescein (FAM) fluorescent label on AS1411 allowed flow cytometry analysis, which demonstrated significantly higher association of AS1411-CB conjugates with MCF-7 breast cancer cells compared with MCF-10 A normal mammary epithelial cells. Confocal microscopy further confirmed preferential localization of AS1411-CB conjugates on the surface of MCF-7 cells, consistent with nucleolin-mediated targeting. These results demonstrated that AS1411-CB conjugates preserved the targeting capability of AS1411 and highlighted its potential as a boron delivery platform for tumor-targeting applications.</p>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"182 ","pages":"110553"},"PeriodicalIF":5.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149014989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bioorganic ChemistryPub Date : 2026-10-15Epub Date: 2026-09-18DOI: 10.1016/j.bioorg.2026.110519
Seyed Jalal Hosseinimehr
{"title":"Targeting overexpressed tumor cell receptors with radiolabeled molecules: Biological targets, clinical applications, and translational challenges.","authors":"Seyed Jalal Hosseinimehr","doi":"10.1016/j.bioorg.2026.110519","DOIUrl":"10.1016/j.bioorg.2026.110519","url":null,"abstract":"<p><p>Cancer remains a leading cause of mortality worldwide, and early diagnosis and effective targeted therapy are often constrained by the lack of tumor-specific biomarkers. Overexpressed cell-surface receptors provide accessible targets for precision molecular imaging and radionuclide therapy, enabling selective visualization and treatment of malignancies while minimizing off-target effects in normal tissues. This review synthesizes the current landscape of biomarker-targeted radiopharmaceuticals, highlighting clinically approved agents, emerging molecular scaffolds, and key criteria for optimal targeting and imaging performance. Clinically approved PSMA- and SSTR2-targeted radiotracers exemplify the success of this approach, enabling highly sensitive and specific detection of prostate cancer and neuroendocrine tumors, respectively. In contrast, many other radiolabeled molecules face substantial challenges in regulatory approval and clinical translation. Overall, exploitation of overexpressed tumor biomarkers for targeted imaging and therapy holds considerable promise for transforming oncology diagnostics and improving patient outcomes through precision molecular medicine.</p>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"182 ","pages":"110519"},"PeriodicalIF":5.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149007660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"2-Azabicyclo[3.2.1]octane-based ALK inhibitors inspired by aconitine scaffold remodeling: design, synthesis, and biological evaluation","authors":"Shuai Guo, Gong-hui Ge, Hao Hu, Ruo-jin wang, Wen-han Xue, Ting-ting Li, Yan-ping Wang, Xu Zhang, Yi-meng Zheng, Hong-ye Liu, Ying-hao Sun, Fan-hao Meng, Ting-jian Zhang","doi":"10.1016/j.bioorg.2026.110662","DOIUrl":"10.1016/j.bioorg.2026.110662","url":null,"abstract":"<div><div>Building on a previously reported aconitine-inspired 2-azabicyclo[3.2.1]octane scaffold, a series of derivatives was designed and synthesized as ALK-directed leads. Compound <strong>14n</strong> showed the lowest measured biochemical ALK IC<sub>50</sub> in the present series (0.73 nM) and a biochemical preference for ALK within the tested kinase panel. It retained inhibitory activity against ALK L1196M and G1202R, with IC<sub>50</sub> values of 10.5 and 88.7 nM, respectively. Compound <strong>14n</strong> exhibited antiproliferative activity in two ALK-positive cell lines, NCI-H2228 and Karpas-299, with IC<sub>50</sub> values of 0.06 and 0.69 μM, respectively. In NCI-H2228 cells, <strong>14n</strong> reduced ALK, AKT, and ERK phosphorylation, induced G0/G1-phase cell-cycle arrest and apoptosis, and reduced wound closure and Transwell migration. In an NCI-H2228 xenograft model, <strong>14n</strong> produced dose-dependent tumor growth inhibition. At 30 mg/kg, its antitumor effect was similar in magnitude to that of ceritinib at the same dose, with no overt toxicity observed under the tested conditions. Molecular docking and molecular dynamics simulations suggested a plausible binding mode within the ALK ATP-binding pocket. These findings identify <strong>14n</strong> as an ALK-directed lead for further optimization.</div></div>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"183 ","pages":"Article 110662"},"PeriodicalIF":5.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149202806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"In vitro enzymatic synthesis of long-acting therapeutic proteins and peptides.","authors":"Gaoshuai Li, Yanlu Zhang, Qicheng Zhu, Yongjun Mao, Yanchao Han, Chenshui Lin, Hongliang Duan, Xudong Wang","doi":"10.1016/j.bioorg.2026.110521","DOIUrl":"10.1016/j.bioorg.2026.110521","url":null,"abstract":"<p><p>The site-specific functionalization of therapeutic proteins and peptides represents a significant challenge in modern synthetic chemistry due to the presence of numerous competing nucleophilic residues. Conventional chemical conjugation strategies not only suffer from poor regioselectivity-leading to high product heterogeneity and compromised bioactivity-but also frequently rely on toxic organic solvents and excessive coupling reagents, directly contradicting the principles of green chemistry. In contrast, biocatalysis has become an effective approach for precision bioconjugation. Operating under mild aqueous conditions, enzymatic transformations offer high regio- and chemoselectivity, high atom economy, and minimal environmental footprint. This review focuses on recent advances in the biocatalytic synthesis of functionalized biomacromolecules, covering four highly efficient green modification strategies: enzymatic glycosylation, lipidation, PEGylation, and macrocyclization. The catalytic mechanisms, substrate specificities, and structural engineering of diverse enzyme classes (e.g., transglutaminases, transpeptidases, ligases, and glycosyltransferases) are discussed in the context of generating homogeneous bioconjugates. Furthermore, we analyze current biocatalytic bottlenecks, such as restricted substrate scopes for unnatural polymers, and provide perspectives on how artificial intelligence (AI)-driven generative enzyme design and synthetic biology will further broaden the scope of biocatalytic methods, promoting the sustainable biomanufacturing of long-acting therapeutic proteins and peptides.</p>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"182 ","pages":"110521"},"PeriodicalIF":5.1,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149011853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Integrating graph attention networks and deep learning with multi-stage computational screening: Bisdemethoxycurcumin as a potent A₂A receptor inhibitor for Parkinson's disease.","authors":"Khaled Otmanine, Mounir Hammoudi, Houari Bendriss, Brahim Feraoun, Selma Mekhane, Nesrine Gherioune, Cherrouk Benmehache, Ichraf Kerrouzi, Khadidja Ayadi, Khaled El Miloudi, Meryem Amal Benghalia, Mustapha Kamel Otmanine, Mohamed Hentabli","doi":"10.1016/j.bioorg.2026.110653","DOIUrl":"https://doi.org/10.1016/j.bioorg.2026.110653","url":null,"abstract":"<p><p>Parkinson's disease (PD) remains a progressive neurodegenerative disorder with limited disease modifying therapies, as current treatments such as L-DOPA offer only symptomatic relief and are associated with severe adverse effects. This study presents an integrated multi-stage computational pipeline that combines quantitative structure activity relationship (QSAR) modelling enhanced by graph attention networks (GATs), molecular docking, density functional theory (DFT), molecular dynamics (MD) simulations, and ADMET profiling to identify natural inhibitors targeting four key PD related proteins: adenosine A₂A receptor (A₂AR), gamma aminobutyric acid type A receptor (GABA-A), nuclear factor erythroid 2- related factor 2 (Nrf2), and (α-synuclein). A comprehensive dataset of 1393 structurally diverse compounds derived from 6- hydroxybenzothiazole 2-carboxamide and related scaffolds was assembled and used to train and validate seven regression algorithms. GATs achieved superior predictive performance (R<sup>2</sup> = 0.991, Q<sup>2</sup> = 0.987, RMSE = 0.487), outperforming Extra Trees (R<sup>2</sup> = 0.742), Random Forest (R<sup>2</sup> = 0.761), and SVR-RBF (R<sup>2</sup> = 0.65). The large dataset size enhanced model generalizability, reduced overfitting risk, and enabled robust feature selection from an expanded descriptor pool of 312 molecular descriptors. Y-randomization with 100 permutations confirmed that all models with meaningful predictive performance were free from chance correlation (ΔQ<sup>2</sup> > 0.50), validating the robustness of the QSAR workflow. Molecular docking of six phytochemicals derived from Curcuma longa (ar-turmerone, α -turmerone, bisdemethoxycurcumin) and Salvia officinalis (camphor, 1,8-cineole, α, β-thujone) revealed that bisdemethoxycurcumin BDMC exhibited the strongest binding affinity to the A₂A receptor (-9.1 kcal/mol) among the evaluated phytochemicals. L-DOPA, the current clinical standard of care, displayed weak affinity to the A₂A receptor (-7.2 kcal/mol), consistent with its known mechanism as a dopamine precursor rather than an A₂A ligand. DFT calculations at the B3LYP/6311G(d,p) level showed that BDMC possessed the lowest HOMO- LUMO energy gap (0.1428 eV) and the highest electrophilicity index (ω = 0.1477), indicating superior chemical reactivity and electron accepting capacity. A 200 ns MD simulation confirmed stable BDMC A₂A receptor binding, with 3-8 (mean ≈ 5) persistent hydrogen bonds and no dissociation events throughout the trajectory, as evidenced by centre of mass distance analysis and principal component analysis. ADMET profiling using SwissADME and ProTox II classified BDMC as blood brain barrier (BBB) permeable, compliant with Lipinski's Rule of Five, and safe (LD₅₀ = 2560 mg/kg, toxicity Class 5), compared to L-DOPA (Class 4, LD₅₀ = 1460 mg/kg). Comparative analysis demonstrated that BDMC offers superior predicted binding affinity to the A₂A receptor and a more favourable predicted toxic","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"184 ","pages":"110653"},"PeriodicalIF":5.1,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149219739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Novel acetophenonic-isoxazoline derivatives with potent anti-cancer and selective COX-2 inhibitory effects: Design, synthesis, and biological evaluation.","authors":"Hoda Abolhasani, Afshin Zarghi, Siavoush Dastmalchi, Ahmad Abolhasani, Hourieh Kalhor, Tahereh Komeili Movahed","doi":"10.1016/j.bioorg.2026.110612","DOIUrl":"https://doi.org/10.1016/j.bioorg.2026.110612","url":null,"abstract":"<p><p>Overexpression of the COX-2 enzyme is a major factor in the development of various malignancies, including colorectal cancer. A new series of acetophenonic-isoxazoline derivatives was designed, synthesized, and evaluated for selective COX-2 inhibitory and anticancer effects. A synthetic route based on the 1,3-dipolar cycloaddition mechanism was employed for the regiospecific formation of the isoxazoline ring. The newly synthesized compounds were characterized by combustion analysis, IR, <sup>1</sup>H NMR, <sup>13</sup>C NMR, and ESI-MS. Cytotoxicity was assessed using the MTT assay against HT-29 human cancer cells and HFF and HEK293 human normal cell lines. In addition, cell cycle analysis, apoptosis induction, and the expression levels of BAX, Bcl-2, caspase-3, PTGS2, and VEGF genes were evaluated in HT-29 cells treated with the most promising derivatives. The most probable binding modes were predicted by docking the 3D structures into the COX-2 binding site (PDB code: 1CX2), and the results showed hydrogen-bond formation with key residues. The fluoro-containing derivative 9b showed superior in vitro COX-2 selectivity (SI = 141.7), whereas compound 9f, bearing a 3,4-dimethoxyphenyl moiety, exhibited the highest COX-2 inhibition (IC<sub>50</sub> = 0.08 μM) and potent cytotoxicity against HT-29 cells (IC<sub>50</sub> = 7.34 ± 2.88 μM). The most potent compounds (9b, 9e, 9f, and 9 g) promoted apoptosis, with significantly increased mRNA expression of BAX and caspase-3 and decreased Bcl-2 expression. Collectively, these findings suggest that the newly designed acetophenonic-isoxazoline derivatives, as COX-2 inhibitors, may exert multitarget therapeutic effects against colorectal cancer.</p>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"184 ","pages":"110612"},"PeriodicalIF":5.1,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149222998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Basima A A Saleem, Aly M Waseem, Kasim Sakran Abass, Stefan Bräse, Ghallab Alotaibi, Abdullah Alkhammash, Abdulrahman A Almehizia, Ahmed M Naglah
{"title":"Novel sulfonamide-containing dihydropyrimidine derivatives as potent inhibitors of tumor-associated carbonic anhydrase isoforms IX/XII: Design, synthesis, and anticancer evaluation.","authors":"Basima A A Saleem, Aly M Waseem, Kasim Sakran Abass, Stefan Bräse, Ghallab Alotaibi, Abdullah Alkhammash, Abdulrahman A Almehizia, Ahmed M Naglah","doi":"10.1016/j.bioorg.2026.110619","DOIUrl":"https://doi.org/10.1016/j.bioorg.2026.110619","url":null,"abstract":"<p><p>Tumor-associated carbonic anhydrases IX and XII (CA IX and CA XII) are crucial regulators of extracellular acidification in hypoxic tumors, supporting cancer cell survival and progression. In this study, a novel series of dihydropyrimidine-sulfonamide hybrids was evaluated for selective inhibition of CA IX and XII and their anticancer potential. Among them, compound 7b exhibited potent dual inhibition of CA IX (IC₅₀ = 0.025 μM) and CA XII (IC₅₀ = 0.02 μM), with minimal off-target activity against CA I and II. In MTT assays, 7b demonstrated strong antiproliferative activity against HT-29 (IC₅₀ = 0.52 μM), 786-O (IC₅₀ = 0.58 μM), and MCF-7 (IC₅₀ = 0.87 μM) cancer cell lines, while showing lower cytotoxicity toward WI-38 normal fibroblasts (IC₅₀ = 23.71 μM), yielding selectivity indices of 27.25-45.60 under the present in vitro conditions. Mechanistic studies in HT-29 cells revealed that 7b induces apoptosis via upregulation of BAX and p53, downregulation of Bcl-2, and activation of caspase-3 and caspase-9, indicating involvement of the mitochondrial pathway. Molecular docking suggested plausible binding modes for 7b within the CA IX and XII active sites, including predicted Zn<sup>2+</sup> coordination and hydrogen-bonding interactions, providing a structural rationale for the experimentally observed inhibitory profile. Taken together, these independent findings demonstrate potent CA IX/XII enzyme inhibition, cellular antiproliferative activity, and apoptosis-associated effects for compound 7b.</p>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"184 ","pages":"110619"},"PeriodicalIF":5.1,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149222972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bioorganic ChemistryPub Date : 2026-10-05Epub Date: 2026-08-18DOI: 10.1016/j.bioorg.2026.110413
Marius Savu, Vasilichia Antoci, Oana Elena Carp, Sergiu Shova, Cristina Mariana Uritu, Miruna Maria Furtuna, Maria-Cristina Al-Matarneh, Mitica Ciorpac, Dorina Amariucai-Mantu, Ionel I Mangalagiu
{"title":"Chimeric pyrrolodiketo-pyrrolidine-phthalazine - triazole derivatives: synthesis, structure, stereochemistry, and anticancer activity.","authors":"Marius Savu, Vasilichia Antoci, Oana Elena Carp, Sergiu Shova, Cristina Mariana Uritu, Miruna Maria Furtuna, Maria-Cristina Al-Matarneh, Mitica Ciorpac, Dorina Amariucai-Mantu, Ionel I Mangalagiu","doi":"10.1016/j.bioorg.2026.110413","DOIUrl":"10.1016/j.bioorg.2026.110413","url":null,"abstract":"<p><p>We present herein a detailed study concerning the design, synthesis, structure, stereochemistry, and anticancer activity of a new class of chimeric pyrrolodiketo-pyrrolidine-phthalazine-triazole (PPPT) derivatives. The design of the chimeric PPPT molecules integrated the biological potential of phthalazine, pyrrolidine, and triazole scaffolds using the Multiple Targeting Ligands (MTL) / molecular hybridization (MH) strategy, along with bioisosteric modifications of existing drugs. The synthesis of our chimeric PPPT derivatives was efficient and straightforward in two steps: a Huisgen 3 + 2 dipolar cycloaddition reaction of ylides with a symmetrically substituted cyclic Z-alkene, followed by a click copper-catalysed reaction. The cycloaddition reactions proceed with high stereospecificity, and NMR and single-crystal X-ray diffraction studies unambiguously established the stereochemistry of the obtained compounds. The anticancer assay reveals that the newly obtained compounds 1, 4a,b, and 6a-j have low or no cytotoxicity toward normal cells and exhibit very good to moderate activity against breast adenocarcinoma and osteosarcoma cancer cell lines. The most active compounds were proved to be the chimeric derivatives 6c, 6d, and 6j, with IC<sub>50</sub> values close to those of the standard drug doxorubicin on the MCF7 and MG-63 cancer cell lines, and with selectivity index values also indicating a good cytotoxic profile. Notable SAR correlations have been observed. The in silico Swiss-ADME evaluation indicates that our chimeric PPPT derivatives exhibit good ADME, drug-likeness, and medicinal chemistry properties. The in silico computational Swiss-Target Prediction tool predicts that our chimeric PPPT compounds will most likely act as Multiple Targeting Ligands, primarily as tyrosine kinase and PARP-1 inhibitors. The in silico molecular docking studies confirm VEGFR-2 and PARP-1 as possible binding sites for our compounds. Both the experimental anticancer assay and the in silico computational studies suggest that our chimeric pyrrolodiketo-pyrrolidine-phthalazine-triazole derivatives 6c, 6d, and 6j are promising drug candidates.</p>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"181 ","pages":"110413"},"PeriodicalIF":5.1,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}